tetano
Editor, Senior Moderator
FASEB Bioadv. 2020 Apr 11;2(5):296-303. doi: 10.1096/fba.2020-00015. eCollection 2020 May.
The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?
Hondermarck H[SUP]1,[/SUP][SUP]2[/SUP], Bartlett NW[SUP]1,[/SUP][SUP]2[/SUP], Nurcombe V[SUP]3,[/SUP][SUP]4[/SUP].
Author information
Abstract
Growth factor receptors are known to be involved in the process of viral infection. Many viruses not only use growth factor receptors to physically attach to the cell surface and internalize, but also divert receptor tyrosine kinase signaling in order to replicate. Thus, repurposing drugs that have initially been developed to target growth factor receptors and their signaling in cancer may prove to be a fast track to effective therapies against emerging new viral infections, including the coronavirus disease 19 (COVID-19).
? 2020 The Authors.
KEYWORDS:
COVID‐19; SARS‐CoV‐2; cancer drugs; growth factors; heparan sulfate; heparin; inhibitors; tyrosine kinase; virus
PMID:32395702PMCID:PMC7211041DOI:10.1096/fba.2020-00015
The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?
Hondermarck H[SUP]1,[/SUP][SUP]2[/SUP], Bartlett NW[SUP]1,[/SUP][SUP]2[/SUP], Nurcombe V[SUP]3,[/SUP][SUP]4[/SUP].
Author information
Abstract
Growth factor receptors are known to be involved in the process of viral infection. Many viruses not only use growth factor receptors to physically attach to the cell surface and internalize, but also divert receptor tyrosine kinase signaling in order to replicate. Thus, repurposing drugs that have initially been developed to target growth factor receptors and their signaling in cancer may prove to be a fast track to effective therapies against emerging new viral infections, including the coronavirus disease 19 (COVID-19).
? 2020 The Authors.
KEYWORDS:
COVID‐19; SARS‐CoV‐2; cancer drugs; growth factors; heparan sulfate; heparin; inhibitors; tyrosine kinase; virus
PMID:32395702PMCID:PMC7211041DOI:10.1096/fba.2020-00015